Gary J. Nabel

TL;DR: The DNA/rAd5 vaccine regimen did not reduce either the rate of HIV-1 acquisition or the viral-load set point in the population studied and had an acceptable side-effect profile.

TL;DR: It is shown that a bnAb with enhanced FcRn binding has increased gut mucosal tissue localization, which improves protection against lentiviral infection in non-human primates and suggests that modification of Fc Rn binding provides a mechanism not only to increase serum half-life but also to enhance mucosal localization that confers immune protection.

TL;DR: A nonhuman primate challenge model with simian immunodeficiency virus (SIV) shows that antibodies to the SIV envelope are necessary and sufficient to prevent infection, and identifies a two-amino-acid signature that alters antigenicity and confers neutralization resistance.

TL;DR: Bispecific antibodies are disclosed that include a first antigen binding domain that specifically binds to an HIV-1 envelope protein (such as gp120 or gp41), and a second antigen bounding domain that is T cell activating and HIV 1 -activating, such as an scFv that specific binds to CD3.

TL;DR: In this paper, the authors proposed a broadly neutralizing antibody for the treatment of HIV infection, which is further characterized by their ability to bind epitopes from the Env proteins.